BioFactura Announces Initiation of Phase I Study of BFI-751, a Stelara® (ustekinumab) Biosimilar

The first-in-human Phase I study initiated by BioFactura Australia Pty Ltd is a bioequivalence randomized, double-blind, trial being conducted in Australia and New Zealand.